|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on recent promising clinical results from CD20-depleting strategies by three therapeutic monoclonal antibodies in clinical phase II and III trials (rituximab, ocrelizumab and ofatumumab), targeting B cells in MS is currently attracting growing interest among basic researchers and clinicians.
|
28450895 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent successes with CD20-depleting antibodies have focused attention towards B cell subsets as important mediators in MS.
|
31617269 |
2020 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis.
|
31542710 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated <sup>64</sup>Cu-rituximab, a radiolabeled antibody specifically targeting the human B cell marker CD20, for its ability to image B cells in a mouse model of MS using PET.
|
28687602 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we provide a brief overview about anti-CD20 B cell-based therapies in MS, in the perspective of their influence on the future management of the disease, and of their possible positioning in a new wider therapeutic scenario.
|
31059839 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the efficacy of anti-CD20 therapy for MS is largely limited because anti-CD20 antibodies target only B cells.
|
23801080 |
2013 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: In this review, the authors discuss the rationale of the depletion of B cells in RRMS and PPMS across recent studies on the role of B cells in the pathogenesis of MS; previous clinical trials with treatments targeting B cells; the mechanism of action of ocrelizumab - a second generation anti-CD20 mAb - and recent phase III clinical trials with ocrelizumab in RRMS and PPMS.
|
30570368 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Last, we summarize remaining unanswered questions regarding the proper role of anti-CD20 therapy in MS, its limitations, and the future landscape of B-cell-based approaches to treatment.Ann Neurol 2018;83:13-26.
|
29244240 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we summarized several applications of anti-CD20 antibodies in various immune related disorders including B-CLL (B-cell chronic lymphocytic leukemia), rheumatoid arthritis (RA), multiple sclerosis (MS) and melanoma.
|
30551501 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD20-mAbs could become first-line drugs in selected patients with highly active MS and already constitute an option for PPMS.
|
31027436 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab is a chimeric monoclonal anti-CD20 B-cell-depleting antibody increasingly used off-label in multiple sclerosis (MS).
|
28762877 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent interest in the key role of B cells in MS has been evoked by the profound anti-inflammatory effects of rituximab, a chimeric monoclonal antibody (mAb) targeting the B cell surface marker CD20, observed in relapsing-remitting MS.
|
31044580 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ocrelizumab, a monoclonal antibody to CD20 on B cells, is a highly effective agent for MS that is likely to be approved soon by the FDA.
|
28130412 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell depletion through anti-CD20 monoclonal antibody utilization and other immunomodulatory therapies have been promising in reducing episodes of relapse and slowing progression, further strengthening the concept that B cells and antibodies are significant players in formation of brain lesions in MS.
|
31577986 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective was to determine whether CD52 lymphocyte depletion can act to promote immunological tolerance induction by way of intravenous antigen administration such that it could be used to either improve efficiency of multiple sclerosis (MS) inhibition or inhibit secondary autoimmunities that may occur following alemtuzumab use in MS. Relapsing experimental autoimmune encephalomyelitis was induced in ABH mice and immune cell depletion was therapeutically applied using mouse CD52 or CD4 (in conjunction with CD8 or CD20) depleting monoclonal antibodies.
|
27925187 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from anti-CD20 therapies demonstrate that B- and T-cell interaction is a major driver of multiple sclerosis (MS).
|
31136008 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD20 monoclonal antibodies in multiple sclerosis.
|
27718747 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Anti-cd20-mediated B-cell depletion using mAbs is a promising therapy for multiple sclerosis.
|
31681317 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical studies indicate that anti-CD20 B-cell depletion may be an effective multiple sclerosis (MS) therapy.
|
20641064 |
2010 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS).
|
31573386 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In recent years, the perception of a respective pathophysiological B cell involvement was vividly promoted by the empirical success of anti-CD20-mediated B cell depletion in clinical trials; based on these findings, the first monoclonal anti-CD20 antibody-ocrelizumab-is currently in the process of being approved for treatment of MS.
|
28946620 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A real-world study from Wales suggests that early initiation of highly effective therapy may provide more benefit that an escalation approach in relapsing MS. A study from the MSBase dataset found evidence that early treatment with highly effective therapies decreased the risk of developing secondary progressive MS. Ocrelizumab is highly efficacious in relapsing MS and in a group of patients with primary progressive MS. Another CD20 directed mAb, ofatumumab, is in phase 3.
|
30985372 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An increased proportion of myelin-specific CD8<sup>+</sup> T cells in MS patients exhibited a memory phenotype and expressed CD20 compared to control subjects, while there were no phenotypic differences observed among influenza-specific CD8<sup>+</sup> T cells.
|
31748274 |
2019 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that in MS patients, increased levels of CD3(+)CD20(dim) T cells are effectively depleted by RTX.
|
24928997 |
2014 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ofatumumab is the first, fully human, anti-CD20 monoclonal antibody in Phase 3 development for multiple sclerosis (MS).
|
31281311 |
2019 |